Novo Nordisk
Novo Nordisk makes the GLP-1 drugs, such as semaglutide, that are the active ingredients in diabetes and weight-loss treatments, placing it at the manufacturing layer of the metabolic pool.
Checked against the company's own business description in its latest annual filing.
Latest disclosed
20-F filed 2026-02-04 · period ending 2025-12-31
Pieces naming this company
None yet.
No price is shown: the Index is a map of what each company sells and where it sits, not a quote board.